In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Lundbeck licenses two Teva Parkinson's disease drugs
13 Dec 1999
Danish CNS drug developer H. Lundbeck in collaboration with Teva (Israel's largest pharmaceutical company), will co-develop the latter's Parkinson's disease drugs: the Phase III Rasagiline and TV 1203, in Phase II. Lundbeck will get exclusive European marketing rights from Teva, which will retain rights in all other territories worldwide.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?